Deregulated apoptosis is a hallmark of cancer, and the B-cell lymphoma-2 (Bcl-2) family of
proteins is pivotal to mediating the intrinsic pathway of this process. Recent advances have …

Introduction The anti-apoptotic BCL-2 family proteins, such as BCL-2, BCL-XL, and MCL-1,
are excellent cancer therapeutic targets. The FDA approval of BCL-2 selective inhibitor …

Bcl-2 and Bcl-xL are critical regulators of apoptosis that are overexpressed in a variety of
human cancers and pharmacological inhibition of Bcl-2 and Bcl-xL represents a promising …

Abstract Antiapoptotic Bcl-2-family proteins Bcl-2 and Bcl-X L have been recently validated
as drug discovery targets for cancer. Here, by using a combination of molecular modeling …

Despite tremendous advances over the last 15 years in understanding fundamental
mechanisms of apoptosis, this has failed to translate into improved cancer therapy for …

Apoptosis, or programmed cell death, plays a key role in normal tissue homeostasis
ensuring a proper balance between cell production and cell loss. Anti-apoptotic Bcl-2-family …

Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are key regulators of the apoptotic
process. This family comprises proapoptotic and prosurvival proteins, and shifting the …

Background: The evidence that pan-Bcl-2 or Bcl-xL-specific inhibitors prematurely kill virus-
infected or RNA/DNA-transfected cells provides rationale for investigating these apoptotic …

Due to their central role in the regulation of apoptosis, the antiapoptotic BCL2‐proteins are
highly promising targets for the development of novel anticancer treatments. To this end …

Dose-limiting toxicity to healthy tissues is among the major hurdles in anticancer treatment
along with intrinsic or acquired multi-drug resistance. Development of small molecule …